Olink Holding AB

Olink Holding AB provides accelerating proteomics together with the scientific community, across multiple disease areas to enable new discoveries and improve the lives of patients. The firm offers a platform of products and services which are deployed across major biopharmaceutical companies and clinical and academic institutions to deepen the understanding of real-time human biology and drive 21st century healthcare through actionable and impactful science. It operates through the following segments: Kit and Service. The company was founded on December 13, 2018 and is headquartered in Uppsala, Sweden.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q3 2024

Olink Holding AB exceeds revenue goals, eyes proteomics market growth

Olink had a successful Q4 and 2022, exceeding revenue goals and showcasing innovation.
The company is poised for growth in the proteomics market with a focus on data quality.
Challenges include shifting revenue mix, expanding installations, and meeting customer demands.
Opportunities lie in developing new assays, expanding the protein library, and leveraging positive customer feedback.

Olink Holding AB reports robust Q1 growth and eyes profitability

Olink Holding AB's Q1 2023 performance reflects strong revenue growth and a focus on innovation in next-generation proteomics.
Despite challenges in certain regions and operating at a net loss, the company maintains positive cash flow and aims for profitability in 2023.
Opportunities lie in market expansion, M&A activities, and improving kit gross margins through R&D efforts.
Overall, Olink's unique positioning in the life science space and commitment to serving diverse customer needs underpin its growth potential.

Olink Holding AB (OLK) sees strong revenue growth and market optimism

Olink Holding AB (OLK) reports solid revenue growth in Q2 2023, driven by Explore revenue and scientific productivity. Despite challenges in profitability and margin improvements, the company is optimistic about the market impact of Explore HT and back-half growth potential.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Olink Holding AB is a company dedicated to accelerating proteomics together with the scientific community, across multiple disease areas to enable new discoveries and improve the lives of patients. Olink provides a platform of products and services which are deployed across major biopharmaceutical companies and leading clinical and academic institutions to deepen the understanding of real-time human biology and drive 21st century healthcare through actionable and impactful science.

UPPSALA, Sweden, March 07, 2022 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced the Nomination Committee's proposal for election of members of the Board of Directors of Olink.

THE NOMINATION COMMITTEE'S PROPOSAL FOR ELECTION OF MEMBERS OF THE BOARD OF DIRECTORS OF OLINK HOLDING AB (PUBL)

Olink Holding AB (publ) (OLK) CEO Jon Heimer on Q4 2021 Results - Earnings Call Transcript

UPPSALA, Sweden, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced its unaudited financial results for the fourth quarter and full year ended December 31, 2021, and provided revenue guidance for the full year 2022.

Olink reports fourth quarter and full year 2021 financial results and provides outlook for 2022

UPPSALA, Sweden, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Nasdaq: OLK) today announced that Sequanta Technologies, a leading multi-omics service provider based in China, will use Olink® Explore 3072 to analyze 1,000 patient samples from a new cohort study in China.

Sequanta selects Olink® Explore 3072 to analyze new cohort study in China

The company posted some impressive anticipated growth figures in a new set of preliminary results.

Why Olink Holding Stock Blasted Higher Today

UPPSALA, Sweden, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced preliminary unaudited revenue for the fourth quarter and year ended December 31, 2021, and additional select unaudited performance metrics.

Olink announces preliminary unaudited revenue for the fourth quarter and full year 2021

UPPSALA, Sweden, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK), today announced that its project with Boehringer Ingelheim, assessing the potential utility of protein biomarkers in the empagliflozin EMPEROR studies, recently entered the data analysis phase.

Olink participates in one of the largest proteomics studies enabling new treatment options for patients with heart failure

UPPSALA, Sweden, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Nasdaq: OLK) today announced that the delivery of Olink ®  Explore 3072 is now starting, providing customers with access to its expanded library of ~3000 carefully curated and validated assays that together cover of all major biological pathways.

Olink® Explore 3072 high-throughput proteomics platform now available: Significantly expands Olink's protein library for biomarker discovery

UPPSALA, Sweden, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Nasdaq: OLK) is proud to announce the winner of the young researchers' award, Novelties in Biomarkers , Melissa Amrein at the University Hospital of Basel, Switzerland at the Biomarkers of the Future conference in Paris, France.

Melissa Amrein, at the University Hospital of Basel, Switzerland, is awarded the 2021 Novelties in Biomarkers prize at the Biomarkers of the Future Conference in Paris, France

UPPSALA, Sweden, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Nasdaq: OLK) today announced that it is now starting the delivery of Olink ®   Signature Q100, facilitating hands-on access for researchers to Olink technology with a new benchtop system dedicated to multiplex protein biomarker measurement.

Olink® Signature Q100 now available: A user friendly desktop instrument to broaden access to Olink's multiplex protein analysis platform

Olink Holding AB (publ) (OLK) CEO Jon Heimer on Q3 2021 Results - Earnings Call Transcript

ROCKVILLE, Md.--(BUSINESS WIRE)-- #DNA--Psomagen, Inc., a North American sequencing-based contract laboratory service and data analysis provider with both CLIA-certified and CAP-accredited facilities, has partnered with Olink Proteomics, which offers an innovative DNA-coupled immunoassay that identifies and quantifies protein biomarkers in clinical samples. The partnership enables end-to-end multi-omics clinical studies, a step that will enable a whole new generation of precision therapies derived fro

Psomagen, Inc. Is Partnering with Olink Proteomics, Enabling Unprecedented Multi-Omics Clinical Studies

UPPSALA, Sweden, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced its financial results for the third quarter of 2021.

Olink reports third quarter 2021 financial results

UPPSALA, Sweden, Nov. 05, 2021 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK), today announced that it will be participating in two investor events in November.

Olink announces participation in November investor events

Strategic Partnership creates an end-to-end multi-omics platform for pharma, clinical research and biomarker discovery leveraging Fulgent's expansive test menu across genomics, transcriptomics, and now, Olink Proteomics. Strategic Partnership creates an end-to-end multi-omics platform for pharma, clinical research and biomarker discovery leveraging Fulgent's expansive test menu across genomics, transcriptomics, and now, Olink Proteomics.

Fulgent Genetics Offers Multi-Omic Solutions to Pharma through Addition of Olink Proteomics Platform

UPPSALA, Sweden, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Nasdaq: OLK), a global leader in proteomics, today announced that it will release financial results for the third quarter of 2021 before the market open on Wednesday, November 10, 2021. Company management will host a conference call to discuss financial results at 8:00 a.m. ET.

Olink to report third quarter 2021 financial results on November 10, 2021

UPPSALA, Sweden, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK), today announced that Jon Heimer, CEO, and Oskar Hjelm, CFO, will participate in the following virtual investor conferences:

Olink to present at two upcoming investor conferences

UPPSALA, Sweden, Aug. 31, 2021 (GLOBE NEWSWIRE) -- CellCarta and Olink Proteomics AB announced today a strategic collaboration to offer Olink® Target 96 & Target 48 to pharmaceutical and biotech customers, advancing targeted protein biomarker quantification in clinical studies.

CellCarta expands its biomarker capabilities for clinical trials by adding Olink technology to its global services

Olink Holding AB (publ) (OLK) Management on Q2 2021 Results - Earnings Call Transcript

UPPSALA, Sweden, July 27, 2021 (GLOBE NEWSWIRE) -- Olink Holding AB ( publ ) (“Olink”) (Nasdaq: OLK) today announced t h at CORAL, a new collaborative community of scientists , will use the Olink Proteomics platform to identify novel protein biomarkers and biological mechanisms for neurological diseases .

Olink: CORAL to use the Olink Proteomics platform to identify novel protein biomarkers and biological mechanisms for neurological diseases

UPPSALA, Sweden, July 21, 2021 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Nasdaq: OLK) today announced that the UK Biobank Pharma Proteomics Project (UKB-PPP Consortium) has decided to expand the ongoing proteomics study of 53,000 participants to the new Olink® Explore 3072 platform, providing access to Olink´s expanded library of approximately 3,000 carefully curated and validated assays.

UK Biobank-PPP expands proteomics study of 53,000 participants to Olink Explore 3072

Olink Holding AB (publ) – ADR (NASDAQ:OLK) shares are trading lower by 11% at $31.94 after the company announced a public offering of 7 million ADSs by selling shareholders. Olink Holding AB has a proprietary and patented Proximity Extension Assay technology, which enables researchers to use one platform for discovery to clinical trials to diagnostic applications utilizing the established infrastructure of labs and installed instrumentation.

Why Olink Shares Are Getting Hammered Today

UPPSALA, Sweden, July 12, 2021 (GLOBE NEWSWIRE) -- Olink Holding AB ( publ ) (“Olink”) (Nasdaq: OLK) today announce d preliminary unaudited revenue and net income (loss) for the second quarter ended June 30, 2021.

Olink announces preliminary financial results for the second quarter 2021

UPPSALA, Sweden, July 12, 2021 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Nasdaq: OLK) (“Olink” or the “Company”), today announced the launch of a public offering of 7,000,000 American Depositary Shares, each representing one common share of the Company (the “ADSs”), to be sold by certain selling shareholders of the Company. In addition, certain of the selling shareholders are expected to grant the underwriters a 30-day option to purchase up to 1,050,000 additional ADSs. The selling shareholders will receive all of the net proceeds from the offering and Olink will not receive any proceeds. The offering is subject to market and other conditions, and there can be no assurance as to whether, or when, the offering may be completed or as to the actual size or terms of the offering.

Olink Holding AB (publ) Launches Public Offering of American Depositary Shares by Selling Shareholders

UPPSALA, Sweden, June 15, 2021 (GLOBE NEWSWIRE) --  Scallop-logo-470-pxOlink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced that the SCALLOP consortium (Systematic and Combined AnaLysis of Olink Proteins), a collaborative framework for discovery and follow-up of genetic associations with proteins on the Olink Proteomics platform, is launching a new clinical trial arm to bring together actors working on proteomic profiling in clinical trials. The new initiative is designed to enhance insights from clinical trial proteomic profiling, boost statistical power and uncover the next level of drug target insights.

News for Olink Holding AB Stock (OLK)